Paroxetine-mediated GRK2 Inhibition to Reduce Cardiac Remodeling After Acute Myocardial Infarction

• Status: Active, not recruiting
• Trial end date: 2021-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This study evaluates the off-target effect of paroxetine to reverse cardiac remodeling and improve left ventricular ejection fraction in patients after acute myocardial infarction. Half of the participants will receive paroxetine, while the other half will receive placebo treatment.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital Inselspital, Berne
• Treatments: Paroxetine

Criteria

Inclusion Criteria:

• Anterior wall ST-segment elevation myocardial infarction

• Primary percutaneous coronary intervention (PCI) within 24 hours of symptom onset

• Left ventricular ejection fraction ≤ 45% within 48-96 hours after primary PCI (transthoracic echocardiography)

Exclusion Criteria:

• Female patients at reproductive age (<50 years)

• Known intolerance to paroxetine

• Inability to provide informed consent

• Currently participating in another trial before reaching first endpoint

• Current medical therapy with MAO-blocker (during, 14 days before, and 14 days after treatment with MAO-blocker), lithium, thioridazide, or pimozide

• Concomitant tamoxifen intake

• Previous myocardial infarction

• Previous revascularization procedure (percutaneous coronary intervention or coronary artery bypass grafting).

• Contraindication to cardiac magnetic resonance imaging

• Obvious or questionable inability to appropriately cooperate (alcohol, drugs etc.)

• Relevant nephropathy or hepatopathy